Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.62 |
| ▸ | MAOB | P27338 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | MGLL | Q99685 | 1/20 | 0.58 |
| ▸ | BCHE | P06276 | 1/20 | 0.56 |
| ▸ | LTA4H | P09960 | 2/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6377153 | 0.92 | LMNA (0.62) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL7036584 | 0.88 | MGLL (0.67) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL9808056 | 0.87 | LMNA (0.72) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL27367676 | 0.85 | LMNA (0.82) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL339813 | 0.85 | LMNA (0.82) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL4884524 | 0.85 | LTA4H (0.58) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL6191729 | 0.85 | LTA4H (0.72) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL9482346 | 0.84 | LTA4H (0.67) | CYP1A2CYP2C19L3MBTL1LTA4H | |
| SCHEMBL9483961 | 0.84 | FFAR1 (0.57) | GAARAB9AL3MBTL1LTA4HEPHX2 | |
| SCHEMBL5238958 | 0.84 | LTA4H (0.66) | LMNACYP1A2PTGS1SLC6A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320214-A1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4493559-A2 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2025-01-22 | — | — | EP | disclosed |
| WO-2023178113-A2 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| EP-1874746-B1 | DERIVATIVES OF 1-N-AZACYCLOALKYL-3-PHENOXYPROPANE USEFUL FOR THE PREPARATION OF PSYCHOTROPIC MEDICAMENTS | BIOPROJET SOC CIV (FR) | 2015-11-18 | — | — | EP | disclosed |
| CN-101258138-B | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine h3-receptor ligands | BIOPROJET SOC CIV | 2013-06-12 | — | — | CN | disclosed |
| US-8076329-B2 | Histamine H3-receptor ligands and their therapeutic applications | BIOPROJET (FR) | 2011-12-13 | — | — | US | disclosed |
| US-20090111808-A1 | NOVEL HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | BIOPROJET (FR) | 2009-04-30 | — | — | US | disclosed |
| CN-101258138-A | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine h3-receptor ligands | BIOPROJET SOC CIV (FR) | 2008-09-03 | — | — | CN | disclosed |
| EP-1874746-A2 | NOVEL HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | BIOPROJET (FR) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006117609-A2 | PHENOXYPROPYLPIPERIDINES AND -PYRROLIDINES AND THEIR USE AS HISTAMINE H3 -RECEPTOR LIGANDS | BIOPROJET (FR) | 2006-11-09 | — | — | WO | disclosed |
| EP-1717234-A1 | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands | BIOPROJET (FR) | 2006-11-02 | — | — | EP | disclosed |
| EP-1717235-A2 | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands | BIOPROJET (FR) | 2006-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111808-A1 | NOVEL HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | HRH3, HRH4, HRH1 | LMNA 4608/4885CYP1A2 1330/4885PTGS1 878/4885 |
| US-20250320214-A1 | ORGANIC COMPOUNDS | OPRD1, OPRK1, OPRM1 | LMNA 4233/4885CYP1A2 199/4885PTGS1 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.